Skip to main content
SpringerLink
Log in

Antipsychotic-induced Extrapyramidal Syndromes in Psychiatric Practice: A Case-control Study

  • Research Article
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

Background: While several clinical trials showed that atypical antipsychotics have a low risk of extrapyramidal side effects (EPS), this observation is not undisputed. This study compared the risk of EPS between specific subgroups of antipsychotics.

Methods: Using the automated dispensing records of a large psychiatric hospital in The Netherlands, we defined cases as first-time users of anticholinergic antiparkinson drugs. Controls were all patients with no recorded use of such medication. Cases and controls were compared with regard to previous use of antipsychotics and relevant co-factors.

Results: Out of 1403 patients, we identified 105 cases and 330 controls. Compared to non-users, antipsychotic-users were 10 times more likely to start with anticholinergic antiparkinson medication (adjusted odds ratio: 10.1; 95 CI 4.6–22.3). Depot and non-depot antipsychotics had similar adjusted odds ratios of 10.9 (95 CI 3.7–32.6) and 8.8 (95% CI 3.8–20.4) respectively. Low and high potency antipsychotics gave odds ratios of 3.0 (95% CI 0.9–10.3) versus 10.8 (95% CI 4.7–25.1). Classical and atypical antipsychotics showed comparable odds ratios: 10.0 (95% CI: 4.4–22.5) versus 8.0 (95% CI: 2.6–24.5). Applied doses of classical and atypical antipsychotic drugs were much lower and more equivalent than those used in previous clincial trials.

Conclusions: Low potency antipsychotics had a much lower risk of EPS than other antipsychotics. However, we did not corroborate the reduced risk with atypical antipsychotics observed in several clinical trials. This discrepancy may result from the high and non-equivalent doses of classical antipsychotics used in many of these trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. CJL Murray AD. Lopez (1996) The Global Burden of Disease and Injury Series, Vol 1: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 Harvard University Press Cambridge, MA

    Google Scholar 

  2. Gijsen R, Roos MJC. Hoe vaak komt schizofrenie voor? In: Volksgezondheid toekomst verkenning, Nationaal kompas volksgezondheid. Bilthoven: RIVM, 2004.

  3. DE. Casey (1991) ArticleTitleNeuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia Schizophr Res 4 IssueID2 109–20 Occurrence Handle10.1016/0920-9964(91)90029-Q Occurrence Handle1674881

    Article  PubMed  Google Scholar 

  4. JT Schwartz AW. Brotman (1992) ArticleTitleA clinical guide to antipsychotic drugs Drugs 44 IssueID6 981–92 Occurrence Handle1282868

    PubMed  Google Scholar 

  5. G Chouinard et al. (1993) ArticleTitleA Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients J Clin Psychopharmacol 13 IssueID1 25–40 Occurrence Handle7683702

    PubMed  Google Scholar 

  6. CM Beasley SuffixJr et al. (1997) ArticleTitleOlanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial Eur Neuropsychopharmacol 7 IssueID2 125–37 Occurrence Handle10.1016/S0924-977X(96)00392-6 Occurrence Handle9169300

    Article  PubMed  Google Scholar 

  7. DL Zimbroff et al. (1997) ArticleTitleControlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group Am J Psychiatry 154 IssueID6 782–91 Occurrence Handle9167505

    PubMed  Google Scholar 

  8. OJ Hoyberg et al. (1993) ArticleTitleRisperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations Acta Psychiatr Scand 88 IssueID6 395–402 Occurrence Handle7508675

    PubMed  Google Scholar 

  9. SK Min et al. (1993) ArticleTitleRisperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial Yonsei Med J 34 IssueID2 179–90 Occurrence Handle7691017

    PubMed  Google Scholar 

  10. CH Miller et al. (1998) ArticleTitleThe prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics J Clin Psychiatry 59 IssueID2 69–75

    Google Scholar 

  11. PI Rosebush MF. Mazurek (1999) ArticleTitleNeurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone Neurology 52 IssueID4 782–5 Occurrence Handle10078728

    PubMed  Google Scholar 

  12. DG Standaert AB. Young (1995) Treatment of central nervous system degenerative disorders LS Goodman A Gilman JG Hardman AG Gilman LE Limbird (Eds) The Pharmacological Basis of Therapeutics EditionNumber9 McGraw-Hill New York 504–20

    Google Scholar 

  13. A. Kuy ParticleVan der (1998) Farmacotherapeutisch Kompas Centrale Medisch Farmaceutische Commissie van de Ziekenfondsraad Amstelveen

    Google Scholar 

  14. CF. George (1997) British National Formulary, September 1997 British Medical Association and the Royal Pharmaceutical Society of Great Britain London

    Google Scholar 

  15. AC Egberts et al. (1997) ArticleTitleChanneling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment J Clin Psychopharmacol 17 IssueID3 149–55 Occurrence Handle10.1097/00004714-199706000-00002 Occurrence Handle9169957

    Article  PubMed  Google Scholar 

  16. InstitutionalAuthorNameAnonymous, Anatomical Therapeutic Chemical (ATC) (1998) Classification Index: Including Defined Daily Doses (DDD) for Plain Substances World Health Organization Oslo, Norway

    Google Scholar 

  17. P Bollini et al. (1994) ArticleTitleAntipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials Psychol Med 24 IssueID2 307–16 Occurrence Handle7916157

    PubMed  Google Scholar 

  18. FJ Jimenez Jimenez PJ Garcia Ruiz JA. Molina (1997) ArticleTitleDrug-induced movement disorders Drug Saf 16 IssueID3 180–204 Occurrence Handle9098656

    PubMed  Google Scholar 

  19. S. Greenland (1989) ArticleTitleModeling and variable selection in epidemiologic analysis Am J Public Health 79 IssueID3 340–9 Occurrence Handle2916724

    PubMed  Google Scholar 

  20. JJ. Schlesselman (1982) Case–control studies Oxford University Press New York 200–6

    Google Scholar 

  21. J Avorn et al. (1995) ArticleTitleNeuroleptic drug exposure and treatment of parkinsonism in the elderly: a case–control study Am J Med 99 IssueID1 48–54 Occurrence Handle10.1016/S0002-9343(99)80104-1 Occurrence Handle7598142

    Article  PubMed  Google Scholar 

  22. L Ganzini et al. (1991) ArticleTitleAcute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study J Geriatr Psychiatry Neurol 4 IssueID4 222–5 Occurrence Handle1686396

    PubMed  Google Scholar 

  23. F. Ayd (1961) ArticleTitleA survey of drug-induced extrapyramidal reactions JAMA 175 IssueID12 1055–60

    Google Scholar 

  24. DB Menkes et al. (1987) ArticleTitleAnticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs Int Clin Psychopharmacol 2 IssueID1 55–67 Occurrence Handle2889760

    PubMed  Google Scholar 

  25. SR Marder RC. Meibach (1994) ArticleTitleRisperidone in the treatment of schizophrenia Am J Psychiatry 151 IssueID6 825–35 Occurrence Handle7514366

    PubMed  Google Scholar 

  26. KJ Rothman S. Greenland (1998) Modern Epidemiology EditionNumber2 Lippincott-Raven Philadelphia

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands

    I. Schillevoort, R. M. C. Herings, A. de. Boer & H. G. M. Leufkens

  2. HC Rümke Groep, Utrecht, The Netherlands

    G. W. K. Hugenholtz & W. A. Nolen

  3. University Medical Centre, Utrecht, The Netherlands

    W. A. Nolen

  4. Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands

    R. A. C. Roos

Authors
  1. I. Schillevoort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. M. C. Herings
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. de. Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. G. M. Leufkens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. W. K. Hugenholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. A. Nolen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. A. C. Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. de. Boer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schillevoort, I., Herings, R.M.C., Boer, A.d. et al. Antipsychotic-induced Extrapyramidal Syndromes in Psychiatric Practice: A Case-control Study. Pharm World Sci 27, 285–289 (2005). https://doi.org/10.1007/s11096-004-5797-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-004-5797-9

Key words

Search

Navigation